Fast Market Research

New Market Research Report: S.L.A. Pharma AG - Product Pipeline Review - 2013

Recently published research from Global Markets Direct, "S.L.A. Pharma AG - Product Pipeline Review - 2013", is now available at Fast Market Research


Boston, MA -- (SBWIRE) -- 08/20/2013 -- Global Market Direct's pharmaceuticals report, "S.L.A. Pharma AG - Product Pipeline Review - 2013" provides data on the S.L.A. Pharma AG's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, S.L.A. Pharma AG's corporate website, SEC filings, investor presentations and featured press releases, both from S.L.A. Pharma AG and industry-specific third party sources, put together by Global Markets Direct's team.

View Full Report Details and Table of Contents


- S.L.A. Pharma AG - Brief S.L.A. Pharma AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of S.L.A. Pharma AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of S.L.A. Pharma AG with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the S.L.A. Pharma AG's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to Get This Report

- Evaluate S.L.A. Pharma AG's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of S.L.A. Pharma AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the S.L.A. Pharma AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with S.L.A. Pharma AG.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of S.L.A. Pharma AG and identify potential opportunities in those areas.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Novartis AG - Product Pipeline Review - 2013
- Bayer AG - Product Pipeline Review - 2013
- Noxxon Pharma AG - Product Pipeline Review - 2013
- S.L.A. Pharma AG - Product Pipeline Review - 2012
- Biotest AG - Product Pipeline Review - 2013
- Wilex AG - Product Pipeline Review - 2013
- Inflammatory Bowel Disease - Pipeline Review, H1 2013
- NOXXON Pharma AG - Product Pipeline Review - 2012
- Pulmonary Hypertension - Pipeline Review, H1 2013
- Post-Operative Pain - Pipeline Review, H1 2013